drugset / Trial / NCT07336758

A Study in Healthy Men to Test How BI 1584862 is Processed in the Body

NCT07336758

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to find out how BI 1584862 moves through and exits the body of healthy men. To do this, BI 1584862 is labelled using radioactive carbon (C-14) and using a non-radioactive, naturally occurring, stable isotope (C-13). The study will measure how much of the study medicine is recovered in urine and faeces after taking it by mouth. It will also look at how much of the study medicine enters the bloodstream when taken by mouth compared to a small dose given directly into the bloodstream. The study staff measures the amount of BI 1584862 and its broken-down parts in the blood, the urine, and the stool.

Timeline

Start
2026-01-22
Primary completion
2026-03-04
Completion
2026-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1584862 Unknown Oral

Indications

No indication recorded.